Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J. Ishiguro T, et al. Among authors: kamata sakurai m. Sci Transl Med. 2017 Oct 4;9(410):eaal4291. doi: 10.1126/scitranslmed.aal4291. Sci Transl Med. 2017. PMID: 28978751
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C, Tanaka E, Kikuchi Y, Wakabayashi T, Wada M, Goto M, Toyoda T, Ueyama A, Suzuki S, Haraya K, Tachibana T, Kawabe Y, Shima M, Yoshioka A, Hattori K. Kitazawa T, et al. Among authors: kamata sakurai m. Nat Med. 2012 Oct;18(10):1570-4. doi: 10.1038/nm.2942. Epub 2012 Sep 30. Nat Med. 2012. PMID: 23023498
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Shiraiwa H, Narita A, Kamata-Sakurai M, Ishiguro T, Sano Y, Hironiwa N, Tsushima T, Segawa H, Tsunenari T, Ikeda Y, Kayukawa Y, Noguchi M, Wakabayashi T, Sakamoto A, Konishi H, Kuramochi T, Endo M, Hattori K, Nezu J, Igawa T. Shiraiwa H, et al. Among authors: kamata sakurai m. Methods. 2019 Feb 1;154:10-20. doi: 10.1016/j.ymeth.2018.10.005. Epub 2018 Oct 13. Methods. 2019. PMID: 30326272
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Kamata-Sakurai M, Narita Y, Hori Y, Nemoto T, Uchikawa R, Honda M, Hironiwa N, Taniguchi K, Shida-Kawazoe M, Metsugi S, Miyazaki T, Wada NA, Ohte Y, Shimizu S, Mikami H, Tachibana T, Ono N, Adachi K, Sakiyama T, Matsushita T, Kadono S, Komatsu SI, Sakamoto A, Horikawa S, Hirako A, Hamada K, Naoi S, Savory N, Satoh Y, Sato M, Noguchi Y, Shinozuka J, Kuroi H, Ito A, Wakabayashi T, Kamimura M, Isomura F, Tomii Y, Sawada N, Kato A, Ueda O, Nakanishi Y, Endo M, Jishage KI, Kawabe Y, Kitazawa T, Igawa T. Kamata-Sakurai M, et al. Cancer Discov. 2021 Jan;11(1):158-175. doi: 10.1158/2159-8290.CD-20-0328. Epub 2020 Aug 25. Cancer Discov. 2021. PMID: 32847940
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment.
Mimoto F, Tatsumi K, Shimizu S, Kadono S, Haraya K, Nagayasu M, Suzuki Y, Fujii E, Kamimura M, Hayasaka A, Kawauchi H, Ohara K, Matsushita M, Baba T, Susumu H, Sakashita T, Muraoka T, Aso K, Katada H, Tanaka E, Nakagawa K, Hasegawa M, Ayabe M, Yamamoto T, Tanba S, Ishiguro T, Kamikawa T, Nambu T, Kibayashi T, Azuma Y, Tomii Y, Kato A, Ozeki K, Murao N, Endo M, Kikuta J, Kamata-Sakurai M, Ishii M, Hattori K, Igawa T. Mimoto F, et al. Among authors: kamata sakurai m. Cell Rep. 2020 Dec 22;33(12):108542. doi: 10.1016/j.celrep.2020.108542. Cell Rep. 2020. PMID: 33357423 Free article.
In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice.
Sugyo A, Tsuji AB, Sudo H, Narita Y, Taniguchi K, Nemoto T, Isomura F, Awaya N, Kamata-Sakurai M, Higashi T. Sugyo A, et al. Among authors: kamata sakurai m. Transl Oncol. 2022 Sep;23:101481. doi: 10.1016/j.tranon.2022.101481. Epub 2022 Jul 9. Transl Oncol. 2022. PMID: 35820360 Free PMC article.
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: kamata sakurai m. Cancer Immunol Res. 2024 Jun 4;12(6):719-730. doi: 10.1158/2326-6066.CIR-23-0638. Cancer Immunol Res. 2024. PMID: 38558120
[No title available]
[No authors listed] [No authors listed] PMID: 38563577
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K, Yoshimoto M, Miura-Okuda M, Uchikawa R, Kato C, Shinozuka J, Akai S, Naoi S, Tomioka N, Nagaya N, Pang CL, Garvita G, Feng S, Shimada M, Kamata-Sakurai M, Aburatani H, Kitazawa T, Igawa T. Kamikawa T, et al. Among authors: kamata sakurai m. J Immunother Cancer. 2024 Oct 14;12(10):e009563. doi: 10.1136/jitc-2024-009563. J Immunother Cancer. 2024. PMID: 39401967 Free PMC article.
14 results